Targeting multiple opioid receptors–improved analgesics with reduced side effects?

T Günther, P Dasgupta, A Mann, E Miess… - British journal of …, 2018 - Wiley Online Library
Classical opioid analgesics, including morphine, mediate all of their desired and undesired
effects by specific activation of the μ‐opioid receptor (μ receptor). The use of morphine for …

The delta opioid receptor in pain control

K Abdallah, L Gendron - Delta Opioid Receptor Pharmacology and …, 2018 - Springer
Nowadays, the delta opioid receptor (DOPr) represents a promising target for the treatment
of chronic pain and emotional disorders. Despite the fact that they produce limited …

Inhibition of the Ubc9 E2 SUMO-conjugating enzyme–CRMP2 interaction decreases NaV1. 7 currents and reverses experimental neuropathic pain

L François-Moutal, ET Dustrude, Y Wang… - Pain, 2018 - journals.lww.com
We previously reported that destruction of the small ubiquitin-like modifier (SUMO)
modification site in the axonal collapsin response mediator protein 2 (CRMP2) was sufficient …

New opioid receptor modulators and agonists

AD Kaye, EM Cornett, SS Patil, SA Gennuso… - Best Practice & …, 2018 - Elsevier
There has been significant research to develop an ideal synthetic opioid. Opioids with
variable properties possessing efficacy and with reduced side effects have been …

Preclinical assessment of utility of M6S for multimodal acute and chronic pain treatment in diabetic neuropathy

JSK Yadlapalli, N Dogra, AW Walbaum, PL Prather… - Life sciences, 2018 - Elsevier
Aims Previous reports from our laboratory have established that morphine-6-O-sulfate (M6S)
is a mixed μ/δ opioid receptor (OR) agonist and a potential improved alternative to morphine …